Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program
Clinical & Experimental Allergy · 2026-04 · 56 (4) · 369-377
DOI: 10.1111/cea.70177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Allergy, online erschienen am 23.11.2025. Verfasst von T W Brettig und 21 weiteren Autor:innen. Beteiligte Einrichtung: National Allergy Centre of Excellence (NACE), Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Peanut Hypersensitivity, Desensitization, Immunologic, Allergens. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Australian Federal Government, Murdoch Children's Research Institute, Melbourne Children's Clinician-Scientist.
Abstract (Originalsprache)
Introduction
Peanut allergy is the most common food allergy in Australian school‐aged children and is rarely outgrown. Access to oral immunotherapy (OIT), a disease‐modifying treatment for food allergy, is limited in many regions of the world, including Australia. Clinical trials show high rates of allergic desensitisation and remission are being achieved, particularly in young children, but significant variability in protocols and implementation prevents large‐scale evaluation of clinical and patient‐reported safety, effectiveness and long‐term outcomes. A standardised national model of care OIT program has not been previously attempted. In Australia, the National Allergy Centre of Excellence partnered with 10 paediatric hospitals to develop and implement the ADAPT OIT Program, which aims to change the trajectory from ‘Allergy Development to an Accelerated Pathway to Tolerance’. The Program was designed after extensive international expert and consumer consultation, and attempts to be pragmatic, feasible by using existing resources, and equitable, with out‐of‐pocket costs to families limited to the purchase of the OIT product, store‐bought peanut flour.
Methods
In July 2024, the ADAPT OIT Program was launched. Infants were considered if they had a history consistent with an IgE‐mediated allergic reaction to peanut < 12 months of age and evidence of sensitisation (peanut SPT ≥ 3 mm; peanut sIgE or ara h 2 sIgE ≥ 0.35kUA/L). A threshold oral food challenge (OFC) was done to confirm a diagnosis of peanut allergy using teaspoon measures (1/64th, 1/32nd, 1/16th, 1/8th, ¼, ½, 1 tsp. peanut flour, cumulative dose of 2435 mg peanut protein), and to determine the OIT starting dose unless the index reaction was a CoFAR Grade 3+. In this case, infants started OIT with a microdose escalation commencing with a red microspoon of peanut flour (3 mg peanut protein) up to a maximum of 1/64th tsp. (15 mg). Up‐dose stage visits were conducted every 4 weeks until the maintenance stage was achieved (1/2 tsp. of peanut flour: 650 mg peanut protein). After 2 years of OIT, infants had an 8‐week period of strict peanut avoidance followed by an OFC to assess for sustained unresponsiveness (SU). Infants were followed up for a minimum of 12 months post SU OFC.
Conclusion
The ADAPT OIT Program aims to make best‐practice peanut OIT accessible to a significant proportion of infants with peanut allergy in Australia. Under a national standardised model, with rigorous and timely evaluation, the Program design enables optimisation over time for maximal impact.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Allergy Centre of Excellence (NACE), Parkville, Victoria, Australia.
- Population Allergy Group, Murdoch Children's Research Institute, Parkville, Victoria, Australia.
- Centre for Food Allergy Research (CFAR), Parkville, Victoria, Australia.
- Department of Paediatric Allergy and Immunology, John Hunter Children's Hospital, Newcastle, New South Wales, Australia.
- University of Newcastle, Newcastle, New South Wales, Australia.
- Department of Allergy and Immunology, The Children's Hospital at Westmead, Westmead, New South Wales, Australia.
ORCID-Profile: T W Brettig, I Bosi, P Loke, M D O'Sullivan, K Preece, K P Perrett
Förderung
- Australian Federal Government
- Murdoch Children's Research Institute
- Melbourne Children's Clinician-Scientist
- NHMRC
- National Health and Medical Research Council
Zitieren
APA
Brettig, T. W., Young, A., Bhatia, R., Bosi, I., Cheung, A., Czech, H., Ford, L. S., Katelaris, C. H., Lloyd, M., Loke, P., McDonald, E., Metcalfe, J., O'Sullivan, M. D., Peake, J., Preece, K., Quinn, P., South, C., Smart, J., Swamy, S., …, & Perrett, K. P. (2026). Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program. Clinical & Experimental Allergy, 56(4), 369-377. https://doi.org/10.1111/cea.70177
Vancouver
Brettig TW, Young A, Bhatia R, Bosi I, Cheung A, Czech H, et al. Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program. Clinical & Experimental Allergy. 2026;56(4):369-377. doi:10.1111/cea.70177
BibTeX
@article{Brettig2026,
author = {Brettig, T W and Young, A and Bhatia, R and Bosi, I and Cheung, A and Czech, H and Ford, L S and Katelaris, C H and Lloyd, M and Loke, P and McDonald, E and Metcalfe, J and O'Sullivan, M D and Peake, J and Preece, K and Quinn, P and South, C and Smart, J and Swamy, S and Wainstein, B K and Wong, M and Perrett, K P},
title = {Developing a Standardised National Model of Care for Treatment of Peanut Allergy in Infants: The ADAPT Peanut Oral Immunotherapy Program},
journal = {Clinical & Experimental Allergy},
year = {2026},
volume = {56},
number = {4},
pages = {369--377},
doi = {10.1111/cea.70177}
}
EUVIMED